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Background: The airway smooth muscle (ASM) cell maintains its own proliferative rate and contributes to the
inflammatory response in the airways, effects that are inhibited by corticosteroids, used in the treatment of
airways diseases.
Objective: We determined the differential expression of mRNAs, microRNAs (miRNAs) and long noncoding
RNA species (lncRNAs) in primary ASM cells following treatment with a corticosteroid, dexamethasone,
and fetal calf serum (FCS).
Methods: mRNA, miRNA and lncRNA expression was measured by microarray and quantitative real-time PCR.
Results: A small number of miRNAs (including miR-150, −371-5p, −718, −940, −1181, −1207-5p, −1915,
and −3663-3p) were decreased following exposure to dexamethasone and FCS. The mRNA targets of these
miRNAs were increased in expression. The changes in mRNA expression were associated with regulation of ASM
actin cytoskeleton. We also observed changes in expression of lncRNAs, including natural antisense, pseudogenes,
intronic lncRNAs, and intergenic lncRNAs following dexamethasone and FCS. We confirmed the change in
expression of three of these, LINC00882, LINC00883, PVT1, and its transcriptional activator, c-MYC. We propose
that four of these lincRNAs (RP11-46A10.4, LINC00883, BCYRN1, and LINC00882) act as miRNA ‘sponges’ for
4 miRNAs (miR-150, −371-5p, −940, −1207-5p).
Conclusion: This in-vitro model of primary ASM cell phenotype was associated with the regulation of several
ncRNAs. Their identification allows for in-vitro functional experimentation to establish causality with the primary
ASM phenotype, and in airway diseases such as asthma and chronic obstructive pulmonary disease (COPD).
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Airway smooth muscle cells (ASMCs) are an integral
part of the airways (from large to small) and contribute
to the airflow obstruction in chronic airway respiratory
diseases such as asthma and chronic obstructive pulmon-
ary disease (COPD) through its contractile properties that
lead to airway narrowing. In addition, ASM cells are in a
state of increased proliferation due to the effect of growth
factors that lead to an increase in ASM mass in these
diseases [1-4]. Furthermore, they are pro-inflammatory,
releasing many cytokines and chemokines [5,6]. The regu-
lation of the contractile and proliferative responses of* Correspondence: m.perry@imperial.ac.uk
1Experimental Studies, National Heart and Lung Institute, Imperial College,
London & Royal Brompton NIHR Biomedical Research Unit, Dovehouse
Street, London SW3 6LY, UK
Full list of author information is available at the end of the article
© 2014 Perry et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.ASM in disease remains unclear. In order to understand
this, we have examined the potential contribution of non-
coding RNA in these processes in ASM cells.
We have recently found that the proliferation and
increased release of IL-6 found in ASM cells from patients
with asthma was under the negative regulation of cyclin
inhibitors, p21WAF1 & p27kip1, which were controlled by
the microRNA; mir-221 [7]. We hypothesized that other
miRNAs may also be involved in other aspects of ASM
function. In addition to the miRNA family of short non-
coding RNAs that consist of less than 200 nucleotides,
there is now accumulating evidence that long noncoding
RNAs (lncRNAs with more than 200 nucleotides) can
regulate multiple biological responses and that changes in
their expression may be related to the development of
disease [8,9].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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importance of miRNAs in ASM function (Extensively
reviewed in [10]) and these only validate the importance
of a handful of miRNAs; let-7a, miR-16, miR-25, miR-26a,
miR-133, miR-143, miR-145, miR-146a and miR-206. Fur-
thermore, there are currently, no studies examining the
roles of lncRNAs in ASM. Therefore, we have adopted a
transcriptomic approach to investigate the differential ex-
pression of mRNAs, miRNAs and lncRNAs in primary
ASM cells and exposed them to a known inducer of
proliferation, fetal calf serum (FCS), and also examined
the effect of the corticosteroid, dexamethasone.Methods
Patient recruitment
Healthy subjects with no previous history of disease were
recruited. Each subject underwent a fiberoptic broncho-
scopic study under sedation with midazolam and topical
anaesthesia to the airways with lidocaine. Airway biopsies
were taken from segmental and sub-segmental airways of
the right lower lobe. This study was approved by the Royal
Brompton & Harefield NHS Trust Ethics committee and
all subjects gave written informed consent. Subject data
are shown in Table 1.ASM cell culture and stimulation
ASM cells were picked from bronchial biopsies and
cultured in Dulbecco’s Modified Eagles Medium (DMEM)
supplemented with 4 mM L-glutamine, 20 U/l of penicil-
lin, 20 μg/ml streptomycin, and 2.5 μg/ml amphotericin B
and 10% foetal calf serum (FCS), as previously described
[7,11]. At confluence, ASM cell cultures exhibited a
typical “hill-and-valley” appearance. Immunofluorescence
techniques for calponin, smooth muscle α-actin and my-
osin heavy chain revealed that > 95% of the cells displayed
the characteristics of smooth muscle cells in culture. CellsTable 1 Subject data
n 9
Age (yrs.) 36.4 ± 12.7
Sex (♂ / ♀) 7 / 2
Smoking history 0
Atopy (n)* 0
Receiving medications (n) 0
FEV1 (L) 4.02 ± 0.48
FEV1 (% Predicted) 104.23 ± 7.28
FEV1/FVC (%) 78.89 ± 5.98
PC20 (mg/ml) > 16
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; PC20,
provocative concentration of methacholine causing a 20% fall in FEV1; N/A:
not available. *Defined as positive skin prick tests to one or more common
aeroallergens. Data shown as mean ± SEM.at passages 3–4 were used for all experiments, from 9
different donors.
Confluent cells were growth-arrested by FCS deprivation
for 24 h in DMEM supplemented with sodium pyruvate
(1 mM), L-glutamine (2 mM), nonessential amino acids
(1:100), penicillin (100 U/ml)/streptomycin (100 μg/ml),
amphotericin B (1.5 μg/ml), and bovine serum albu-
min (0.1%). Cells were pre-treated with dexamethasone
(10−7 M) for 1 h, before being stimulated with 2.5% FCS
for 24 h. Supernatants were removed and IL-6 and CXCL8
levels determined by DuoSet ELISA (R&D Systems). Cell
proliferation was measured by the Cell Proliferation
ELISA BrdU kit (Roche Applied Science), an assay com-
parable to cell counting as confirmed by flow cytometry
[7,11]. Cellular viability was assessed by MTT assay [12].
Each patient sample was replicated over 3 wells.
RNA extraction
Total RNA was extracted using the mirVana™ miRNA
isolation kit (Ambion Europe). RNA was eluted in 50 μl
RNase-free water (Promega UK, Southampton, UK) and
stored at −80°C. RNA content and purity was measured
using a BioTek PowerWave XS (SSi Robotics, Tustin,
CA, U.S.A.) spectrophotometer.
Microarray analysis
LncRNA and mRNA expression was determined using the
Agilent SurePrint G3 Human GE microarrays and miRNA
expression was determined using Agilent Human miRNA
microarray following the manufacturer’s instructions.
Total RNA samples (50 ng) used in lncRNA and mRNA
microarrays were initially labeled with Spike-In control A
(for Cyanine 3-CTP) or B (for Cyanine 5-CTP). Labelled
samples were then used for cDNA synthesis using the
cDNA Master Mix (Agilent) and were incubated for 2 h at
40°C followed by 15 min at 70°C to inactivate the Affinity-
Script enzyme. The synthesized cDNA was then used for
cRNA synthesis and amplification using the Transcription
Master Mix with either Cyanine 3 or Cyanine 5 and
incubated at 40°C for 2 h.
Labeled and amplified RNA was then purified using
the RNeasy Mini Kit (Qiagen) and quantified using the
NanoDrop Spectrophotometer’s Microarray Measurement
function. The Cyanine 3 or Cyanine 5 concentrations and
the cRNA concentration were used to calculate the yield
(μg) and the specific activity (pmol Cy3 or Cy5 per μg
cRNA) of each sample. For each microarray reaction,
300 ng of Cyanine 3- and 300 ng of Cyanine 5-labelled,
linearly amplified cRNA samples were mixed and incu-
bated together with Fragmentation buffer for 30 min,
followed by the addition of Hybridization buffer. Samples
were loaded onto SurePrint G3 (8 × 60 K) microarray
slides (Agilent) and hybridized at 65°C for 17 h at 10 rpm
using Agilent’s Hybridization oven and SureHyb chamber.
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GE Wash Buffer 1 (Agilent) for 60 sec at RT, followed by
GE Wash Buffer 2 for 60 sec at 37°C, followed by an
acetonitrile wash (10 sec at RT) and the final wash in
Stabilization and Drying solution for 30 sec at RT, to im-
prove microarray results by preventing ozone-mediated
fluorescent signal degradation. The microarrays were
scanned with the Agilent Microarray Scanner G2565BA
using the profile for 2-colour microarrays (AgilentG3_
GX_2Color) at 5 μm resolution, dyes channel Red&Green,
Scan Area 61 × 21.6 mm.
miRNA-enriched RNA samples (100 ng) used in the
microRNA microarrays were labeled with the Labeling
Spike-In solution using Agilent’s miRNA Complete
Labeling and Hyb Kit and then the samples were de-
phosphorylated by incubation at 37°C on a heat block
for 30 min. DMSO was added to the dephosphorylated
RNA for denaturation for 10 min, followed by the
assembly of the Labeling Reaction, where samples were
incubated with Cyanine 3-pCp and allowed to ligate for
2 h at 16°C. The labeled RNA was purified using Micro
Bio-Spin 6 columns (Bio-Rad) and the desalted samples
were dried up in a vacuum concentrator at 50°C for 1 h
to remove DMSO. Samples were resuspended in Hybridiza-
tion Mix using Hyb Spike-In solution and Hybridization
Buffer and were loaded onto Agilent Human miRNA mi-
croarrays and hybridized at 55°C for 20 h at 20 rpm using
Agilent’s Hybridization oven and SureHyb chamber. The
microarrays were then disassembled and washed in GE
Wash Buffer 1 (Agilent) for 60 sec at RT, followed by GE
Wash Buffer 2 for 60 sec at 37°C. The microarrays were
scanned with the Agilent Microarray Scanner G2565BA
using the profile for miRNA microarrays (AgilentHD_
miRNA) at 2 μm resolution, dye channel Green, Scan
Area 61 × 21.6 mm.
Following normalization against internal controls pro-
vided within the labeling kits, probes which had back-
ground expression (signal value of mRNA < 4.5 and
miRNA < 5.0) were removed. The threshold of back-
ground expression was determined using samples that
processed but which contained no RNA. Since initial
analysis of mRNA, lncRNA and miRNA between baseline
and FCS-treated cells or dexamethasone + FCS-treated
cells showed none that gave a FDR < 0.1, differential ex-
pression (p value) was determined by 3-way ANOVA
using the Partek Genomics Suite. We report changes
in expression with p < 0.05. Predicted interactions be-
tween miRNAs and mRNA were determined using
TargetScan 5.2 within the Partek Genomics Suite. The
changes in profile of mRNA expression were analyzed
using the bioinformatics database, DAVID 6.7 [13,14]
and possible miRNA–lncRNA interactions, were exam-
ined using LNCipedia 2.0 [15]. Microarray data has been
deposited at GEO.Quantitative PCR measurement of miRNA and mRNA
expression
miRNA and lncRNA expression was undertaken with
the 2-step Applied Biosystems TaqMan RT-PCR protocol
(Applied Biosystems) and normalized to 18S, as previously
described [7,11,16]. mRNA expression was determined
using TaqMan RT-PCR with Assays on Demand (Applied
Biosystems). The separate-well 2-(ΔΔCt) method was used
to determine relative quantitative levels of individual
miRNAs, lincRNAs and mRNAs.
Data and statistical analysis
The RT-PCR results are presented as the mean ± SEM of
at least nine independent experiments. Statistical ana-
lysis was performed by Mann–Whitney U-test test, as-
suming non-parametric distribution. P values of < 0.05
were considered significant.
Results
Effect of Dexamethasone and FCS upon ASM cell
proliferation, IL-6 and CXCL8 release
We have previously demonstrated that 2.5% v/v FCS and
10−7 M dexamethasone are optimum concentrations to
induce and, conversely, inhibit both a pro-inflammatory
and proliferative state in primary ASM [7,11,17].
To confirm activation, in this study, of primary ASM
by the stimulus (FCS), and pre-treatment with corticoster-
oid (dexamethasone), we measured DNA synthesis, IL-6,
and CXCL8 release by ELISA. At 24 h, FCS (2.5%) in-
duced DNA synthesis by ~2.5-fold (p < 0.001), IL-6
release ~3-fold (p < 0.001) and CXCL8 release ~2-fold
(p < 0.001) (Figure 1A, C & D). When ASM cells were
exposed to dexamethasone (10−7 M) for 1 h prior to
stimulation with FCS, this increase was completely atte-
nuated (p < 0.001) (Figure 1A, C & D). No effect was ob-
served upon cellular viability (Figure 1B).
Effect of dexamethasone and FCS upon mRNA expression
Following stimulation with FCS (2.5%) 525 mRNA
were increased in expression and 680 were decreased
(Additional file 1: Table S1 & S2). Following treatment
with Dexamethasone (10−7 M) for 1 h before subsequent
stimulation with FCS (2.5%) 436 mRNA were increased in
expression and 457 were decreased (Additional file 1:
Table S3 & S4). Interestingly, only 5 mRNAs were differ-
entially expressed in primary ASM cells after treatment
with FCS or dexamethasone + FCS. The pre-treatment of
the ASM cells with dexamethasone, prevented the subse-
quent change induced by FCS as confirmed by RT-PCR
(Figure 2 and Table 2). For the first time, we report here
the differential expression of these mRNAs in primary
ASM cells.
To identify the pathways that these mRNAs are in-
volved in, we analysed the changes in profile of mRNA
Figure 1 Effect of dexamethasone and FCS upon primary ASM cell proliferation, IL-6 and CXCL8 release. ASM cells were incubated
with dexamethasone (10−7 M) for 1 h before being stimulated with FCS (2.5%) for 24 h. DNA synthesis (A), cell viability (B), IL-6 (C) and CXCL8
(D) release were measured by BrdU ELISA, DuoSet ELISA or MTT assay, respectively. Bars represent mean ± SEM from 9 primary ASM cells.
***/###p < 0.001.
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6.7 (http://david.abcc.ncifcrf.gov/) [13,14]. Significantly,
this showed a deregulation of those mRNAs involved
in inflammatory and other signalling pathways in primary
ASM cells following stimulation with FCS (2.5%). These
included those involved in ASM cell signalling (the NOD-Figure 2 Effect of dexamethasone and FCS upon mRNA expression in
(10−7 M) for 1 h before being stimulated with FCS (2.5%) for 24 h. To valida
TaqMan RT-PCR. Bars represent mean ± SEM from 9 primary ASM cells. +++p
###p < 0.001 vs. baseline.like receptor signalling pathway, cell cycle and p53 sig-
nalling pathway) and inflammation (Cytokine-cytokine
receptor interaction and the TGF-β signaling pathway).
Interestingly, when the same ASM cells were pre-treated
with dexamethasone (10−7 M) before being stimulated
with FCS (2.5%), these pathways were not activated, andprimary ASM cells. ASM cells were incubated with dexamethasone
te the array data, the expression of 5 mRNAs were confirmed by
< 0.001 vs. 18S; */#p < 0.05 vs. baseline; **/##p < 0.01 vs. baseline;
Table 2 Differential mRNA expression changes in healthy ASM cells after treatment with FCS or Dex + FCS
mRNA FCS Dex + FCS
Microarray (FC) qRT-PCR (FC) Microarray (FC) qRT-PCR (FC)
FAM71F1 −1.7 (<.05) −1.62 (<.05) 1.7 (<.05) 1.56 (<.05)
METTL7A −1.9 (<.01) −0.85 (<.05) 2.1 (<.01) 5.77 (<.01)
PLSCR4 −1.5 (<.001) −0.33 (<.05) 1.6 (<.001) 6.47 (<.001)
TUBB3 1.5 (<.05) 1.22 (<.05) −1.7 (<.001) −2.18 (<.05)
WDFY4 −1.8 (<.05) −3.60 (<.01) 1.8 (<.05) 2.01 (<.05)
This table lists those mRNAs that were differentially expressed in healthy ASM cells following stimulation with FCS (2.5%) or treatment with dexamethasone
(10−7 M) before stimulation with FCS (2.5%). Microarray data are denoted as the fold change against baseline control and is the mean of 9 individual patients.
These values are derived from Additional file 1: Table S1, S2, S3, S4 and are for those genes that demonstrated an FDR of less than 0.05; associated P values are
shown in parentheses. FC, Fold change.
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alanine and tyrosine metabolism) (Table 3).
miRNA expression levels in primary ASM cells and their
respective targets
We extracted RNA from ASM cells and measured the
expression of the miRNAs. At baseline, we detected 230
miRNAs (Additional file 1: Table S5). Following exposure
to FCS (2.5%), 10 of these were decreased in expression; a
further 3 more were decreased in expression when the
ASM cells were exposed to dexamethasone prior to
addition of FCS (Table 4). We determined the expression
of 6 of these miRNAs by RT-PCR and confirmed that the
expression of miR-371-5p, −718, −1181, −1207-5p, −1915,
and −3663-3p were reduced by dexamethasone and FCS
(Figure 3).
We utilized the miRNA target prediction program
TargetScan (http://www.targetscan.org/) to review the
targets of these miRNAs. Of the miRNAs decreased
in expression following FCS, 3 have predicted mRNA
targets that were subsequently increased in expression
(Additional file 1: Table S1 & S3). To identify the pathwaysTable 3 Pathway analysis in primary ASM cells
Gene set name P-value*
2.5% FCS
Cell cycle 0.0045
NOD-like receptor signalling pathway 0.0046
Cytokine-cytokine receptor interaction 0.05
P53 signalling pathway 0.03
TGF-β signalling pathway 0.02
2.5% FCS + 10−7 M dexamethasone
Phenylalanine metabolism 0.011
Tyrosine metabolism 0.04
Pathway analysis of those mRNAs changed in expression using the
bioinformatics database, DAVID 6.7 (http://david.abcc.ncifcrf.gov/). *Modified
Fisher Exact P-Value, EASE Score (Maximum Probability). The threshold of EASE
Score, a modified Fisher Exact P-Value, for gene-enrichment analysis. Fisher
Exact P-Value = 0 represents perfect enrichment. P-Value is equal or smaller
than 0.05 to be considered strongly enriched in the annotation categories.
Default is 0.1.that these mRNAs are involved in, we analysed the
changes in profile of mRNA expression using the bioinfor-
matics database, DAVID 6.7 (http://david.abcc.ncifcrf.gov/)
[13,14]. This showed that these mRNAs are essential in
regulation of the actin cytoskeleton, the remodelling
of which is an important mechanism of airway smooth
muscle contraction [18]. We confirmed the increased
expression of these mRNAs by RT-PCR (Figure 4).
lncRNA expression levels in primary ASM cells
Long noncoding RNAs may regulate multiple biological
pathways that could lead to the development of disease.
Currently, lncRNAs can be broadly divided into 4 families
based on their sequence and relative position to the
exonic regions of protein-coding sequences and include
pseudogenes, natural antisense (to exonic regions), in-
tronic lncRNAs, and intergenic lncRNAs [19]. To identify
novel lncRNAs, we used ENSEMBLE (www.ensembl.org/
index.html) to determine the genomic position of those
probe sets from the microarray that did not match known
protein-coding genes.
Following stimulation with FCS, 17 lncRNAs were
increased (Additional file 1: Table S6) and 40 lncRNAs
were decreased in expression (Additional file 1: Table S7).
In the presence of dexamethasone (10−7 M) and FCS, the
lncRNA expression profile changed dramatically with 27
lncRNAs increasing and 39 decreasing in expression
(Additional file 1: Tables S8 & S9, respectively). Interest-
ingly, 29 lncRNAs were altered after FCS and after dexa-
methasone + FCS (Table 5). We confirmed the increased
expression of LINC00882, LINC00883, and PVT1 onco-
gene by RT-PCR, and found them to be significantly
increased in expression in primary ASM cells that had
been pre-treated with dexamethasone (10−7 M), before
being stimulated with FCS (2.5%) (P < 0.05) (Figure 5).
Furthermore, PVT1 is known to be transcriptionally acti-
vated by the oncogene c-MYC and p53 both of which
were increased in expression in our screen of mRNAs,
and we confirmed the expression of c-MYC by RT-PCR,
and in a similar pattern to the PVT1 we found it to be
significantly increased in expression in primary ASM cells
Table 4 miRNA expression changes in healthy ASM cells after treatment with FCS or Dex + FCS
miRNA Baseline expression (ΔCT) FCS Dex + FCS
Microarray (FC) qRT-PCR (FC) Microarray (FC) qRT-PCR (FC)
hsa-miR-134 6.1 (<.001) - - −1.5 (<.001) −1.32 (<.05)
hsa-miR-150* 6.2 (<.001) - - −1.5 (<.001) −1.25 (<.05)
hsa-miR-371-5p 6.3 (<.001) −1.6 (<.001) −0.97 (<.05) −1.7 (<.001) −1.73 (<.05)
hsa-miR-718 5.4 (<.001) −1.5 (<.001) −1.26 (<.05) −1.6 (<.001) −1.44 (<.05)
hsa-miR-762 7.6 (<.001) −1.7 (<.001) - −1.9 (<.001) -
hsa-miR-940 6.7 (<.001) −1.5 (<.001) - −1.6 (<.001) -
hsa-miR-1181 7.0 (<.001) −1.7 (<.001) −0.89 (<.05) −1.8 (<.001) −0.89 (<.05)
hsa-miR-1207-5p 7.7 (<.001) −1.8 (<.001) −1.73 (<.05) −2.0 (<.001) −1.13 (<.05)
hsa-miR-1915 9.0 (<.001) −1.8 (<.001) −0.58 (<.05) −1.9 (<.001) −0.66 (<.05)
hsa-miR-3663-3p 8.0 (<.001) −1.8 (<.001) −1.10 (<.05) −2.0 (<.001) −1.36 (<.05)
hsa-miR-3665 9.7 (<.001) −2.1 (<.001) - −2.3 (<.001) -
hsa-miR-4271 6.1 (<.001) - - −1.5 (<.001) -
hsa-miR-4281 9.6 (<.001) −1.6 (<.001) - −1.5 (<.001) -
This table lists those miRNAs that were differentially expressed in healthy ASM cells following stimulation with FCS (2.5%) or treatment with dexamethasone (10–7 M)
before stimulation with FCS (2.5%). Baseline expression levels are expressed as Δ cycle threshold (ΔCT) and have been normalized against RNU44. Microarray data are
denoted as the fold change against baseline control and is the mean of 9 individual patients. These values are for those genes that demonstrated an FDR of less than
0.05; associated P values are shown in parentheses. FC, Fold change.
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ing stimulated with FCS (p < 0.05) (Figure 5).
Finally, we reviewed the possibility of some of these
expressed lncRNAs acting as miRNA ‘sponges’, a concept
well documented (69). For possible miRNA–lncRNA in-
teractions, we consulted the online database LNCipedia
2.0 (http://lncipedia.org/). We found that 4 lncRNAs
were predicted to act as miRNA ‘sponges’ for miRNAs
that were detected in our screen. For example, RP11-
46A10.4 has complementary regions for miR-1207
(12 sites) and −150 (4 sites). LINC00883 has a binding
region for miR-150 (6 sites), BCYRN1 is proposed to beFigure 3 Effect of dexamethasone and FCS upon miRNA
expression in primary ASM cells. ASM cells were incubated with
dexamethasone (10−7 M) for 1 h before being stimulated with FCS
(2.5%) for 24 h. To validate the array data, the expression of 6 miRNAs
were confirmed by TaqMan RT-PCR. Bars represent mean ± SEM from 9
primary ASM cells. */#p < 0.05 vs. baseline.complementary for miR-150 (49 sites), −940 (14 sites)
and −371 (18 sites), and LINC00882 is complementary
for miR-371 (7 sites). However, to confirm these in-
teractions, subsequent binding studies will need to be
undertaken.
Discussion
We have made several important observations in the ex-
pression profiles of non-coding RNAs, including mRNAs,
miRNAs and lncRNAs in primary human ASM cells,
following stimulation with a well-characterised inducer of
proliferation and inflammatory mediator release (FCS),
and treatment with a corticosteroid (dexamethasone).
Of all the mRNAs that we examined, only 5 were dif-
ferentially expressed following treatment. These included
a methyltransferase (METTL7A) which is a type of
transferase enzyme that transfers a methyl group from a
donor to an acceptor, a scramblase (PLSCR4) which is a
protein responsible for the translocation of phospho-
lipids between the two monolayers of a lipid bilayer of a
cell membrane [20], a member of the tubulin family
(TUBB3) which plays a critical role in proper axon guid-
ance and maintenance and is expressed in non-small cell
lung cancer [21] and WDFY4, a protein with unknown
function but is predominantly expressed in primary and
secondary immune tissues [22]. Of those mRNA changed
in expression, we have previously reported upon the
action of many of these in primary human ASM cells.
For example, disintegrin and metalloprotease proteins
(ADAMs) inhibit ASM cell adhesion and migration
through the β(1)-integrin [23]. Here, we demonstrate
Figure 4 Effect of dexamethasone and FCS upon the predicted mRNA targets of miRNAs decreased in expression in primary ASM cells.
ASM cells were incubated with dexamethasone (10−7 M) for 1 h before being stimulated with FCS (2.5%) for 24 h. 9 mRNAs were changed in
expression following treatment. To validate the array data, the expression of these mRNAs were confirmed by TaqMan RT-PCR. Bars represent
mean ± SEM from 9 primary ASM cells. */#p < 0.05 vs. baseline; **/##p < 0.01 vs. baseline; ###p < 0.001 vs. baseline.
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with FCS (2.5%) (ADAM19 & ADAMTS4) (Additional
file 1: Table S1), and two more were decreased in ex-
pression after stimulation with FCS (2.5%) (ADAM8 &
ADAMTS10) (Additional file 1: Table S2) and both of
these were further decreased in expression when the ASM
cells were pre-treated with dexamethasone (10−7 M)
before subsequent stimulation with FCS (ADAM8 &
ADAMTS10) (Additional file 1: Table S4). Furthermore,
4 additional ADAMs were increased in expression when
the ASM cells were pre-treated with dexamethasone
(10−7 M) before subsequent stimulation with FCS
(ADAM28, ADAMTS1, ADAMTS4, and ADAMTS9),
and the previously up-regulated ADAM19 was further
increased in expression (Additional file 1: Table S3). ASM
cells pre-treated with dexamethasone (10−7 M) before
subsequent stimulation with FCS resulted in the decreased
expression of a further 3 (ADAMTS14, ADAMTS19, and
ADAMTSL1) (Additional file 1: Table S4). Furthermore,
we have previously demonstrated that CCL11 (Eotaxin), is
not only released in higher concentrations from ASM cells
of patients with asthma compared to nonasthmatic con-
trol subjects, but also that dexamethasone can’t repress
this release effectively in asthmatic patients [2]. This
comprehensive screen of mRNAs shows that CCL11 is
decreased in expression in response to FCS stimulation
(Additional file 1: Table S2) and pre-treatment with dexa-
methasone before stimulation results in a further decrease
in expression (Additional file 1: Table S4). Interestingly,
activation of NF-κB may be the basis for increased expres-
sion of many inflammatory genes and for the perpetuation
of chronic airway inflammation in asthma [24]. Once
again, we show that 2 mRNAs essential for the de-activa-
tion of NF-κB are decreased in expression following
stimulation with FCS. This includes NFKBIE, which binds
to components of NF-kappa-B, trapping the complex in
the cytoplasm and preventing it from activating genes inthe nucleus, and NFKBIZ, involved in regulation of NF-κB
transcription factor complexes (Additional file 1: Table S2).
ASM cells are able to express the toll-like receptors,
TLR1 to TLR10 via different stimuli. We demonstrated
that dexamethasone inhibited cytokine- and ligand-
induced TLR2, TLR3, and TLR4 expression and che-
mokine release. However, dexamethasone potentiated
TLR2 expression induced by combined IFN-gamma and
TNF-alpha stimulation [25]. Here we see that TLR2 is
decreased in expression following stimulation with FCS
(Additional file 1: Table S2) and is further reduced when
the cells are pre-treated with dexamethasone before said
stimulation (Additional file 1: Table S4). Interestingly,
TLR4 was increased in expression when the cells are
pre-treated with dexamethasone before said stimulation
(Additional file 1: Table S3). Additionally, we have pre-
viously demonstrated that IRAK-1 mRNA expression is
significantly decreased in expression following IL-1β
stimulation, in ASM cells [17]. Here we show that ASM
cells pre-treated with dexamethasone before stimulation
with FCS causes an increase in expression of IRAK1
(Additional file 1: Table S3). Here we demonstrate that
FCS induces IL-6 release from primary ASM cells. We
have previously found that TGF-β induced the expression
of NOX4 and was accompanied by elevated IL-6 release
in ASM cells [26]. Further studies revealed a role for
SMAD3 pathways. ASM cells treated with dexame-
thasone, before stimulation with FCS, further increases
the expression of NOX4 (Additional file 1: Table S3), and
decreases the expression of SMAD3 (Additional file 1:
Table S4). Finally, and most recently, we have previ-
ously shown that the cyclin-dependent inhibitor p27KIP1
(CDKN1B) is vitally important in driving the hyperproli-
feration seen in ASM cells from asthmatics [7]. Here we
see that cells treated with dexamethasone before stimula-
tion with FCS show a decreased expression in this inhibitor
(Additional file 1: Table S4).
Table 5 Common lncRNA expression changes in healthy ASM cells after treatment with FCS or Dex + FCS
FCS Dex + FCS
Class of lncRNA Ensemble gene ID Transcript Microarray (FC) Microarray (FC)
Known sense overlapping ENST00000314957 CTD-2201E18.3 −1.73 (<.01) 1.78 (<.05)
lincRNA ENST00000414120 LINC00887 −1.81 (<.05) −1.93 (<.01)
Known antisense ENST00000415647 RP11-46A10.4 −1.62 (<.05) −1.65 (<.05)
lincRNA ENST00000417485 AC012668.2 −2.28 (<.01) −1.81 (<.01)
lincRNA ENST00000418539 BCYRN1 −1.53 (<.05) 2.37 (<.05)
Known antisense ENST00000420095 LMCD1-AS1 −1.57 (<.05) 5.65 (<.05)
lincRNA ENST00000426635 LINC00472 1.86 (<.05) 2.64 (<.05)
lincRNA ENST00000431759 SLC2A1-AS1 −1.95 (<.05) −2.09 (<.05)
lincRNA ENST00000433843 SNHG5 −1.74 (<.05) −1.51 (<.01)
lincRNA ENST00000442316 AC074363.1 −1.60 (<.05) −1.62 (<.05)
lincRNA ENST00000444958 DANCR 2.59 (<.05) 2.38 (<.05)
Known antisense ENST00000446423 SDCBP2 −1.82 (<.05) −1.82 (<.05)
lincRNA ENST00000448738 RP1-295F6.2 1.62 (<.05) 1.53 (<.05)
lincRNA ENST00000451910 RP11-344J7.2 2.06 (<.01) 1.66 (<.05)
Known retained intron ENST00000453698 SNHG11 −2.85 (<.01) −2.24 (<.01)
lincRNA ENST00000473636 LINC00882 2.14 (<.05) 2.08 (<.05)
lincRNA ENST00000495228 LINC00883 1.63 (<.05) 1.78 (<.05)
lincRNA ENST00000505448 RP11-774O3.3 −1.57 (<.001) −1.66 (<.05)
Known antisense ENST00000507963 NR2F1-AS1 −1.66 (<.05) −1.61 (<.05)
Known antisense ENST00000509179 MEF2C-AS1 −2.59 (<.05) −2.16 (<.01)
lincRNA ENST00000515296 CTB-35F21.1 −1.83 (<.05) −1.94 (<.05)
lincRNA ENST00000515306 CTB-35F21.2 −2.23 (<.05) −2.15 (<.05)
lincRNA ENST00000515871 CTC-325J23.3 1.60 (<.05) 1.72 (<.01)
lincRNA ENST00000518765 RP11-527N22.1 −1.69 (<.05) −1.53 (<.05)
lincRNA ENST00000518771 RP11-37B2.1 −1.85 (<.001) −1.71 (<.001)
lincRNA ENST00000521128 CTB-43E15.3 −2.07 (<.05) −2.06 (<.05)
lincRNA ENST00000523242 CTB-43E15.1 −1.79 (<.05) −2.02 (<.05)
lincRNA ENST00000523328 PVT1 1.39 (<.01) 1.66 (<.001)
lincRNA ENST00000538996 AP003486.1 −2.69 (<.01) −1.81 (<.05)
This table lists those lncRNAs that have been manually annotated in the Ensembl database and the expression of which is significantly changed in healthy ASM
cells after stimulation with FCS (2.5%) or treatment with dexamethasone (10−7 M) before stimulation with FCS (2.5%). Microarray data are denoted as the fold
change against baseline control and is the mean of 9 individual patients. These values are for those genes that demonstrated an FDR of less than 0.05; associated
P values are shown.
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http://respiratory-research.com/content/15/1/58We then proceeded to measure the expression of miR-
NAs in our human primary ASM cells. Over 200 miRNAs
were detected, and we detected a change in the expression
of a handful of these miRNAs following subsequent
stimulation with FCS and treatment with dexamethasone.
All of these miRNAs have previously been shown to be
associated with cancer, for example, miR-371-5p is associ-
ated with gastric cancer [27], miR-718 with breast cancer
[28], miR-1181 with ovarian cancer [29], miR-1207-5p is
associated with a novel cancer treatment, isoliquiritigenin
[30], miR-1915 is associated with drug resistance in colo-
rectal cancer [31] and miR-3663-3p is associated with skincancer [32]. Although these miRNAs have a role in aber-
rant cellular proliferation, this is the first time that these
miRNAs have reported to be expressed in proliferating
primary ASM cells. However, miR-1915 and −1207
have been previously reported to be increased in ex-
pression in asthmatic epithelial cells from airway
brushings [33], and miR-1207 has been shown to be
associated with vascular smooth muscle proliferation
[34]. Furthermore, we propose that the decreased ex-
pression of three of these miRNAs (miR-371-5p, −940
and −1207-5p), allows for the expression of their tar-
get mRNAs which are involved in critical aspects of ASM
Figure 5 Effect of dexamethasone and FCS upon lncRNA expression in primary ASM cells. ASM cells were incubated with dexamethasone
(10−7 M) for 1 h before being stimulated with FCS (2.5%) for 24 h. To validate the array data, the expression of LINC00882, LINC00883, c-MYC and
PVT1 were confirmed by TaqMan RT-PCR. Bars represent mean ± SEM from 9 primary ASM cells. */#p < 0.05.
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http://respiratory-research.com/content/15/1/58cell cycle regulation such as regulation of microtubule
structure, actin-filament dynamics and later stage cell
cycle progression, although targeting studies need to be
performed to confirm this [35-43].
lncRNAs are widely expressed and yet their import-
ance in physiological and pathological response has only
recently been elucidated [8,44]. They are known to have
a mechanism of action upon activation of common tran-
scription factors such as NF-κB, Sox2, p53, Oct4 and
Nanog [45]. We detected the altered expression of 29
lncRNAs following FCS stimulation, and dexametha-
sone + FCS treatment, including small nucleolar RNA
host gene 5 (previously U50HG), known to be expressed
in human B-cell lymphoma [46]; SDCBP2 antisense
which is increased in expression in non-small cell lung
cancer [47]; and small nucleolar host gene 11. 8 lncRNAs
were increased in expression, including LINC00472
which is expressed in renal tissue [48] and small nu-
cleolar host gene 13 (also known as DANCR) and 3lncRNAs were differentially expressed between stimula-
tion with FCS and those with dexamethasone and FCS
which included brain cytoplasmic RNA 1 (also known as
BC200) which is highly expressed in the hypothalamus
[49] and is deregulated in lung cancer [50], and two novel
lncRNAs; ENST00000314957 AND ENST00000420095.
We validated our array data by confirming the expression
of PVT1, and its transcriptional activator c-MYC. This
lncRNA has been previously implicated in diabetes and
cancer [51-53]. It has been demonstrated that PVT1 is
overexpressed in ovarian and breast cancer cells and when
this expression is inhibited by siRNAs, cell proliferation is
decreased and apoptosis increased [53]. PVT1 is a down-
stream target of c-MYC that targets and binds PVT1,
subsequently driving its transcription [52]. Interestingly
both c-MYC and PVT1 are part of the same locus known
to be frequently overexpressed in cancer [53] and c-MYC
is an important oncogene known to increase cancer cell
growth and proliferation [54]. Furthermore, it is known
Figure 6 Proposed ncRNA interactions in primary airway smooth muscle cells following treatment with dexamethasone before
stimulation with FCS. ASM cells were incubated with dexamethasone (10−7 M) for 1 h before being stimulated with FCS (2.5%) for 24 h. The
lincRNAs RP11-46A10.4, LINC00883, BCYRN1 and LINC00882 act as ‘sponges’ for the miRNAs −1207, −150, −940 and −371. This, in turn, allows for
the mRNA targets of these miRNAs to be expressed.
Perry et al. Respiratory Research 2014, 15:58 Page 10 of 12
http://respiratory-research.com/content/15/1/58that PVT1 expression can be directly induced by p53, as
well as expressing a cluster of 6 miRNAs, including miR-
1207-5p, which as stated above is decreased in expression
in the primary ASM cells [55].
Finally, we address the possibility of lncRNAs acting
as miRNA ‘sponges’, a concept well documented [56].
We utilized the online data base LNCipedia 2.0
(http://lncipedia.org/) and found that that 4 lncRNAs
were predicted to act as miRNA ‘sponges’ for those
miRNAs, that were seen to be decreased in expres-
sion. We propose that the lincRNAs RP11-46A10.4,
LINC00883, BCYRN1 and LINC00882 act as ‘sponges’
for the miRNAs −1207, −150, −940 and −371 and
that this allows for the mRNA targets of these miRNAs
to be expressed, as summarised in Figure 6. Again, these
interactions need to be confirmed with knock-down
studies.
In summary, using a transcriptomics-based approach,
we have demonstrated that primary human ASM cells
have a transcript expression profile associated with an
activated phenotype and have shown that these changes
might, in part, be mediated through alterations in non-
coding RNA expression. Clearly, it is important to con-
firm these observations by examining the expression
of these lncRNAs in primary ASM cells from patients
with asthma and then to follow up these observa-
tions by targeting specific lncRNAs (such as gain and
loss-of-function studies). These studies are currently
on-going.Additional file
Additional file 1: Table S1. Up-regulated mRNAs in healthy ASM cells
after stimulation with FCS. Table S2. Down-regulated mRNAs in healthy
ASM cells after stimulation with FCS. Table S3. Up-regulated mRNAs in
healthy ASM cells after stimulation with Dex + FCS. Table S4. Down-
regulated mRNAs in healthy ASM cells after stimulation with Dex + FCS.
Table S5. Baseline levels of miRNAs in healthy ASM. Table S6. lncRNAs
increased in expression in healthy ASM cells after stimulation with FCS.
Table S7. lncRNAs decreased in expression in healthy ASM cells after
stimulation with FCS. Table S8. lncRNAs increased in expression in
healthy ASM cells after stimulation with Dex + FCS. Table S9. Changes
in expression of lncRNAs in healthy ASM cells after stimulation with
Dex + FCS.
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